BR112021024664A2 - Tratamentos de angioedema hereditário - Google Patents

Tratamentos de angioedema hereditário

Info

Publication number
BR112021024664A2
BR112021024664A2 BR112021024664A BR112021024664A BR112021024664A2 BR 112021024664 A2 BR112021024664 A2 BR 112021024664A2 BR 112021024664 A BR112021024664 A BR 112021024664A BR 112021024664 A BR112021024664 A BR 112021024664A BR 112021024664 A2 BR112021024664 A2 BR 112021024664A2
Authority
BR
Brazil
Prior art keywords
treatments
hereditary angioedema
hae
demand
present
Prior art date
Application number
BR112021024664A
Other languages
English (en)
Portuguese (pt)
Inventor
Andreas Maetzel
Martyn Yea Christopher
Paul Feener Edward
David Smith Michael
Louise Marsh Sally
Original Assignee
Kalvista Pharmaceuticals Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Kalvista Pharmaceuticals Ltd filed Critical Kalvista Pharmaceuticals Ltd
Publication of BR112021024664A2 publication Critical patent/BR112021024664A2/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/12—Antidiarrhoeals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/10—Antioedematous agents; Diuretics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration

Landscapes

  • Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Dermatology (AREA)
  • Diabetes (AREA)
  • Pain & Pain Management (AREA)
  • Otolaryngology (AREA)
  • Pulmonology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Rheumatology (AREA)
  • Hematology (AREA)
  • Hospice & Palliative Care (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicinal Preparation (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
BR112021024664A 2019-06-14 2020-06-15 Tratamentos de angioedema hereditário BR112021024664A2 (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201962861725P 2019-06-14 2019-06-14
GBGB1910116.1A GB201910116D0 (en) 2019-07-15 2019-07-15 Treatments of hereditary angioedema
PCT/GB2020/051439 WO2020249977A1 (en) 2019-06-14 2020-06-15 Treatments of hereditary angioedema

Publications (1)

Publication Number Publication Date
BR112021024664A2 true BR112021024664A2 (pt) 2022-05-31

Family

ID=67700145

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112021024664A BR112021024664A2 (pt) 2019-06-14 2020-06-15 Tratamentos de angioedema hereditário

Country Status (34)

Country Link
US (1) US20220218680A1 (enExample)
EP (2) EP4282474A3 (enExample)
JP (3) JP7356518B2 (enExample)
KR (1) KR102748728B1 (enExample)
CN (1) CN114126612A (enExample)
AR (1) AR119158A1 (enExample)
AU (1) AU2020293614B2 (enExample)
BR (1) BR112021024664A2 (enExample)
CA (1) CA3142218A1 (enExample)
CL (2) CL2021003244A1 (enExample)
DK (1) DK3982960T3 (enExample)
EA (1) EA202193019A1 (enExample)
ES (1) ES2956471T3 (enExample)
FI (1) FI3982960T3 (enExample)
GB (1) GB201910116D0 (enExample)
HR (1) HRP20230696T1 (enExample)
HU (1) HUE063163T2 (enExample)
IL (1) IL288615A (enExample)
LT (1) LT3982960T (enExample)
MA (1) MA56187B1 (enExample)
MD (1) MD3982960T2 (enExample)
MX (1) MX2021014557A (enExample)
MY (1) MY205687A (enExample)
PH (1) PH12021552966A1 (enExample)
PL (1) PL3982960T3 (enExample)
PT (1) PT3982960T (enExample)
RS (1) RS64412B1 (enExample)
SG (1) SG11202113304YA (enExample)
SI (1) SI3982960T1 (enExample)
SM (1) SMT202300261T1 (enExample)
TW (1) TW202112370A (enExample)
UA (1) UA129869C2 (enExample)
WO (1) WO2020249977A1 (enExample)
ZA (1) ZA202110685B (enExample)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB201609607D0 (en) 2016-06-01 2016-07-13 Kalvista Pharmaceuticals Ltd Polymorphs of N-(3-Fluoro-4-methoxypyridin-2-yl)methyl)-3-(methoxymethyl)-1-({4-((2-oxopy ridin-1-yl)methyl)phenyl}methyl)pyrazole-4-carboxamide and salts
GB201719881D0 (en) 2017-11-29 2018-01-10 Kalvista Pharmaceuticals Ltd Solid forms of plasma kallikrein inhibitor and salts thereof
GB201910116D0 (en) * 2019-07-15 2019-08-28 Kalvista Pharmaceuticals Ltd Treatments of hereditary angioedema
CN114206852A (zh) 2019-08-09 2022-03-18 卡尔维斯塔制药有限公司 血浆激肽释放酶抑制剂
WO2022084693A1 (en) * 2020-10-23 2022-04-28 Kalvista Pharmaceuticals Limited Treatments of angioedema
JP2024505596A (ja) 2021-02-09 2024-02-06 カルビスタ・ファーマシューティカルズ・リミテッド 遺伝性血管性浮腫の治療
CA3255900A1 (en) 2022-04-27 2023-11-02 Kalvista Pharmaceuticals Limited FORMULATIONS OF A PLASMA KALLICEREIN INHIBITOR
CN116003386B (zh) * 2022-11-20 2024-03-26 药康众拓(北京)医药科技有限公司 一种氘代n-苄基吡啶酮吡唑甲酰胺类化合物、药物组合物和用途
WO2025172693A1 (en) 2024-02-13 2025-08-21 Kalvista Pharmaceuticals Limited Oral sebetralstat for the treatment of an attack of hereditary angioedema
WO2025172692A1 (en) 2024-02-13 2025-08-21 Kalvista Pharmaceuticals Limited Oral sebetralstat for the treatment of an attack of hereditary angioedema

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5187157A (en) 1987-06-05 1993-02-16 Du Pont Merck Pharmaceutical Company Peptide boronic acid inhibitors of trypsin-like proteases
GB9019558D0 (en) 1990-09-07 1990-10-24 Szelke Michael Enzyme inhibitors
SE9301911D0 (sv) 1993-06-03 1993-06-03 Ab Astra New peptide derivatives
US5589467A (en) 1993-09-17 1996-12-31 Novo Nordisk A/S 2,5',N6-trisubstituted adenosine derivatives
GB0205527D0 (en) 2002-03-08 2002-04-24 Ferring Bv Inhibitors
US7429604B2 (en) 2004-06-15 2008-09-30 Bristol Myers Squibb Company Six-membered heterocycles useful as serine protease inhibitors
JP5322935B2 (ja) 2006-07-31 2013-10-23 アクティベサイト ファーマシューティカルズ インコーポレイティッド 血漿カリクレインの阻害薬
DE102006050672A1 (de) 2006-10-24 2008-04-30 Curacyte Discovery Gmbh Hemmstoffe des Plasmins und des Plasmakallikreins
JP2013121919A (ja) 2010-03-25 2013-06-20 Astellas Pharma Inc 血漿カリクレイン阻害剤
WO2012004678A2 (en) 2010-07-07 2012-01-12 The Medicines Company (Leipzig) Gmbh Serine protease inhibitors
WO2012009009A2 (en) 2010-07-14 2012-01-19 Addex Pharma S.A. Novel 2-amino-4-pyrazolyl-thiazole derivatives and their use as allosteric modulators of metabotropic glutamate receptors
US9290485B2 (en) 2010-08-04 2016-03-22 Novartis Ag N-((6-amino-pyridin-3-yl)methyl)-heteroaryl-carboxamides
GB2494851A (en) 2011-07-07 2013-03-27 Kalvista Pharmaceuticals Ltd Plasma kallikrein inhibitors
GB201300304D0 (en) 2013-01-08 2013-02-20 Kalvista Pharmaceuticals Ltd Benzylamine derivatives
ES2626968T3 (es) 2013-05-23 2017-07-26 Kalvista Pharmaceuticals Limited Derivados heterocíclicos
EP2815749A1 (en) * 2013-06-20 2014-12-24 IP Gesellschaft für Management mbH Solid form of 4-amino-2-(2,6-dioxopiperidine-3-yl)isoindoline-1,3-dione having specified X-ray diffraction pattern
EP2886107A1 (en) * 2013-12-17 2015-06-24 ObsEva S.A. Oral formulations of pyrrolydine derivatives
GB201421083D0 (en) 2014-11-27 2015-01-14 Kalvista Pharmaceuticals Ltd Enzyme inhibitors
GB201721515D0 (en) * 2017-12-21 2018-02-07 Kalvista Pharmaceuticals Ltd Dosage forms comprising a plasma kallikrein inhibtor
GB201910116D0 (en) * 2019-07-15 2019-08-28 Kalvista Pharmaceuticals Ltd Treatments of hereditary angioedema

Also Published As

Publication number Publication date
MA56187A (fr) 2022-04-20
PH12021552966A1 (en) 2022-07-25
EA202193019A1 (ru) 2022-03-24
IL288615A (en) 2022-02-01
LT3982960T (lt) 2023-08-25
DK3982960T3 (da) 2023-08-21
HRP20230696T1 (hr) 2023-10-13
UA129869C2 (uk) 2025-08-27
RS64412B1 (sr) 2023-09-29
WO2020249977A1 (en) 2020-12-17
MX2021014557A (es) 2022-01-11
CN114126612A (zh) 2022-03-01
ES2956471T3 (es) 2023-12-21
ZA202110685B (en) 2024-06-26
AU2020293614B2 (en) 2024-08-15
KR102748728B1 (ko) 2024-12-30
JP2023166406A (ja) 2023-11-21
FI3982960T3 (fi) 2023-08-29
TW202112370A (zh) 2021-04-01
NZ782935A (en) 2025-02-28
EP3982960A1 (en) 2022-04-20
US20220218680A1 (en) 2022-07-14
GB201910116D0 (en) 2019-08-28
CA3142218A1 (en) 2020-12-17
SG11202113304YA (en) 2021-12-30
SMT202300261T1 (it) 2023-09-06
KR20220024220A (ko) 2022-03-03
MA56187B1 (fr) 2023-09-27
PL3982960T3 (pl) 2024-01-15
JP7356518B2 (ja) 2023-10-04
MD3982960T2 (ro) 2023-12-31
JP2022536287A (ja) 2022-08-15
MY205687A (en) 2024-11-06
EP4282474A3 (en) 2024-02-14
JP2025124716A (ja) 2025-08-26
JP7688078B2 (ja) 2025-06-03
CL2023000639A1 (es) 2023-10-30
CL2021003244A1 (es) 2022-09-30
SI3982960T1 (sl) 2023-10-30
AU2020293614A1 (en) 2022-01-27
EP3982960B1 (en) 2023-06-28
EP4282474A2 (en) 2023-11-29
AR119158A1 (es) 2021-12-01
PT3982960T (pt) 2023-09-26
HUE063163T2 (hu) 2023-12-28

Similar Documents

Publication Publication Date Title
BR112021024664A2 (pt) Tratamentos de angioedema hereditário
JOP20220008A1 (ar) مثبطات parp1
CL2021003243A1 (es) Tratamientos de angioedema
MX2008010355A (es) Combinaciones que comprenden inhibidores de proteasa del virus de la hepatitis c e inhibidores de polimerasa del virus de la hepatitis c, y metodos de tratamiento relacionados con los mismos.
NI200900106A (es) Inhibidores de la actividad de la akt.
WO2020047352A8 (en) Plasma kallikrein inhibitors and uses thereof for treating hereditary angioedema attack
BR112013001753A2 (pt) método para preparar uma composição d einter-alfa-inibidor (iaip) eriquecida de plasma, solução aquosa de iaip, e, método para tratar uma doença ou distúrbio associado com disfunção de iaip e associado com atividadede protease de serina no plasma aumentada.
NO20076054L (no) Imidiazo - og triazolopyridiner som inhibitorer av 11-beta-hydroksysteroid-dehydrogenase type I
BR112014008807A2 (pt) compostos de tetra-hidroisoquinolina substituídos como inibidores do fator xia
BR112018011622A2 (pt) método para tratar ataque de angioedema hereditário (hae) ou reduzir a taxa de ataque de hae
AU2016255707A8 (en) Uses of cannabidiol for treatment of infantile spasms
ATE534378T1 (de) Titrierung von tapentadol
BR112014002141A2 (pt) crizotinib para uso no tratamento de câncer
BRPI0416268A (pt) composições de delta-9-thc e métodos para o tratamento de sintomas associados à esclerose múltipla
PH12022550130A1 (en) Enzyme inhibitors
BRPI0508254A (pt) métodos e composições para o tratamento ou prevenção de distúrbios psiquiátricos com inibidores de cox-2 sozinhos e em combinação com agentes antidepressivos
PH12021550883A1 (en) Crystalline salts of a plasma kallikrein inhibitor
BR112022012283A2 (pt) Combinações
AR062779A1 (es) Tratamiento de la esclerosis multiple (em)
BR112022001138A2 (pt) Métodos de tratamento de esclerose múltipla
EP4234022A3 (en) Betahistine, or a pharmaceutically acceptable salt thereof, and a monoamine oxidase inhibitor, for use in the treatment or prevention of one or more symptoms of vertigo in a subject
WO2022063869A3 (en) Compounds for the treatment of viral infections
WO2020055906A8 (en) Methods of treating cancer by inhibiting ubiquitin conjugating enzyme e2 k (ube2k)
BR112019004896A2 (pt) administração sublingual ou bucal de dim para o tratamento de doenças da pele
MX2016011002A (es) Tratamiento de angioedema hereditario con inhibidor c1.

Legal Events

Date Code Title Description
B154 Notification of filing of divisional application [chapter 15.50 patent gazette]

Free format text: O PEDIDO FOI DIVIDIDO NO BR122023019665-1 PROTOCOLO 870230085137 EM 25/09/2023 18:00.

B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B09B Patent application refused [chapter 9.2 patent gazette]